Global Pharma major Pfizer is discussing with the Indian government an expedited approval pathway to make Pfizer-BioNTech vaccine available for use in the country, the company s Chairman and CEO Albert Bourla said on Monday. Earlier in April, Pfizer said that it had offered a not-for-profit price for its vaccine for the government immunisation programme in India and it remains committed to continuing engagement with the government to make the vaccine available in India. Pfizer is aware that access to vaccines is critical to ending this pandemic. Unfortunately, our vaccine is not registered in India although our application was submitted months ago. We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country, Bourla said in a mail sent to Pfizer India employees that he has shared on his LinkedIn post.
At present the vaccination drive in the US has gathered pace and Pfizer has already committed its supply to exports, and to the UN-initiative, GAVI Vaccine Alliance.